microdosing glp 1 agonists GLP-1 Drugs: What To Know Microdosing GLP-1s: How (and Why)

The DELIVER trial randomized 6,263 patients with symptomatic HF, 74% of whom had NYHA class II symptoms, either with HF with moderately reduced ejection fraction (HFmrEF

As exenatide was the same active ingredient in both groups, this data suggests that PK profile significantly influences pharmacological activity of short-acting versus long-acting GLP-1 RAs, resulting in differential reduction of PPG and FPG levels

Do GLP-1 receptor agonists have cardiovascular benefits

[DOI] [PubMed] [Google Scholar] [5].Marathe PH, Gao HX, Close KL, American Diabetes Association Standards of Medical Care in Diabetes 2017, Journal of diabetes, 9 (2017) 320324

Dissemination to participants and related patient and public communities: The authors intend to disseminate these results through social media, press releases, and their website (bwhpromise.org)